Sosei Group Corporation
We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases.
We have established partnerships with some of the world’s leading pharmaceutical companies and multiple emerging technology companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.
“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.
Established |
June 22, 1990 |
|---|---|
Capital |
41,335 million yen (as of 31 December 2022) |
Scope of Business |
Planning strategy for the entire Group and managing subsidiary companies |
Representative Executive Officer, Chairman, President and Chief Executive Officer |
Chris Cargill |
Securities Code |
4565-JP |
Accounting Period |
12 months ended 31 December |
Number of Employees |
202 (consolidated figure, as of end of December 2022) |
Corporate Headquarters |
PMO Hanzomon 11F |
Company Registration Number and Date |
0100-01-021288 registered on 22 June 1990 |
Sosei Group Corporation London Branch
Scope of Business |
Corporate representation in the UK |
|---|---|
Address |
North West House, |
Company Registration Number and Date |
FC024112 registered on 01 April 2002 |
UK Branch Registration Number and Date |
BR006736 registered on 01 April 2002 |
VAT Number |
GB 809812124 |
Sosei Co. Ltd.
Capital |
JPY 90,000,000 |
|---|---|
Scope of Business |
Drug development, manufacture and sales, and business development in Japan |
Representative Director |
Chris Cargill |
Holding Company Stake |
100% |
Address |
PMO Hanzomon 11F |
Company Registration Number and Date |
0100-01-103556 registered on 02 October 2006 |
Heptares Therapeutics Ltd.
Capital |
GBP 416,000 |
|---|---|
Scope of Business |
Drug discovery based on targeting of G protein-coupled receptors |
Representative Director |
Matt Barnes |
Holding Company Stake |
100% |
Address |
Steinmetz Building, Granta Park |
Company Registration Number and Date |
06267989 registered on 04 June 2007 |
VAT Number |
GB 912562244 |
EORI Number |
GB 912562244000 |
Data Protection Registration Number and Date |
Z1055500 registered on 21 September 2007 |
Heptares Therapeutics Ireland Limited
Capital |
EUR 100 |
|---|---|
Scope of Business |
Corporate representation in the EU |
Representative Director |
Chris Cargill |
Holding Company Stake |
100% by Heptares Therapeutics Ltd in UK |
Address |
c/o Byrne Wallace LLP |
Company Registration Number and Date |
656998 registered on 16 September 2019 |